Table 1.
Mendelian randomization estimates for associations of genetically mimicking NK3R antagonists (based on rs116646027 and rs1351623, TACR3) with ischemic heart disease in men and the control outcomes (ischemic heart disease in women, relative age voice broke, number of children fathered, self-reported hypertension and prostate cancer in men) per standard deviation lower testosterone in men from the UK Biobank (http://www.nealelab.is/uk-biobank) and the PRACTICAL consortium23 (prostate cancer).
| Outcome | sex | type | estimate | 95% confidence interval | p-value | Q statistic (p-value) |
|---|---|---|---|---|---|---|
| Odds ratio | ||||||
| Ischemic heart disease | men | main | 0.54 | 0.31 to 0.94 | 0.030 | 0.67 (0.41) |
| women | control | 0.79 | 0.33 to 1.87 | 0.591 | 0.01 (0.92) | |
| beta | ||||||
| Relative age voice broke | men | control | 0.16 | 0.10 to 0.21 | 6.2e-9 | 0.89 (0.34) |
| Number of children | men | control | -0.15 | -0.28 to -0.02 | 0.021 | 1.07 (0.30) |
| Odds ratio | ||||||
| Hypertension | men | control | 0.60 | 0.43 to 0.84 | 0.003 | 0.47 (0.49) |
| Prostate cancer | men | control | 0.60 | 0.39 to 0.91 | 0.016 | 0.70 (0.40) |
The data underlying this table is given in Supplementary Table 3.